Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc.
Your view on RVPH
Overview
What the company does, where it operates, and who runs it.
About Reviva Pharmaceuticals Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laxminarayan Bhat
- Headquarters
- 19925 Stevens Creek Boulevard, Cupertino, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laxminarayan Bhat
- Headquarters
- 19925 Stevens Creek Boulevard, Cupertino, CA, US
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases.
The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.
It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Reviva Pharmaceuticals Holdings, Inc., and the rating behind it. RVPH last traded at $0.53; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Reviva Pharmaceuticals Holdings, Inc.. Starting points for Reviva Pharmaceuticals Holdings, Inc.: EPS -$185316.19, beta -0.04 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Reviva Pharmaceuticals Holdings, Inc.. Reviva Pharmaceuticals Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Reviva Pharmaceuticals Holdings, Inc.. Trailing twelve-month EPS for Reviva Pharmaceuticals Holdings, Inc. stands at -$185316.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Reviva Pharmaceuticals Holdings, Inc.. Reviva Pharmaceuticals Holdings, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Reviva Pharmaceuticals Holdings, Inc. valued side by side against its closest peers. Reviva Pharmaceuticals Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Reviva Pharmaceuticals Holdings, Inc., and how their positions are changing. At a $36.3M market value, institutional positions materially move Reviva Pharmaceuticals Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Reviva Pharmaceuticals Holdings, Inc. executives and directors. Shares of Reviva Pharmaceuticals Holdings, Inc. have traded between $0.25 and $4.28 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Reviva Pharmaceuticals Holdings, Inc.. Reviva Pharmaceuticals Holdings, Inc. is a $36.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Reviva Pharmaceuticals Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Reviva Pharmaceuticals Holdings, Inc.. Coverage tracks Reviva Pharmaceuticals Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.